Disease-a-month

Status Of GLP-1 drugs and their application in treating substance use disorders: A systematic review

By Pugazhendi Inban, Ashita Agrawal, Kakarala Rushika, Jobby John

Figure 1 from Disease-a-month — Figure 1. Inban et al.

Systematic review of studies in peopleInterventions

The paper

Pugazhendi Inban, Ashita Agrawal, Kakarala Rushika, Jobby John

St Mary's General Hospital and St Clare's Health; Dr. Somervell Memorial CSI Medical College and Hospital

Disease-a-month, 9 Oct 2026

doi.org/10.1016/j.disamonth.2026.102231 PubMed 42855378

Neurology Genetics4 Oct 2026
GLP-1 receptor agonists link to lower stroke and Alzheimer risk
Diabetes, Obesity & Metabolism8 Oct 2026
Diabetes drug class linked to slightly less frailty progression
Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs